Spotlight
Video

ESMO 2010 - Dr. Suresh Ramalingam, MD from Emory, Randomized phase 2 study of PF299804, an irreversible human epidermal growth factor receptor (EGFR) inhibitor, versus (v) erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSC

Loading........
Description: Randomized phase 2 study of PF299804, an irreversible human epidermal growth factor receptor (EGFR) inhibitor, versus (v) erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC) after chemotherapy (CT) failure: quantitative and qualitative benefits
Shared By : europe_meeting_2010
Posted on : 10/10/10
Added : 7 years ago
Category : Other



More From europe_meeting_2010

Nothing found.